ZYBERNO
Stock Report
Updated Aug 23, 2026

ASPIRE BIOPHARMA HOLDINGS, INC. (ASBP)

Healthcare • NASDAQ

$7.97

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
27.0/100
POOR BUSINESS
ASPIRE BIOPHARMA HOLDINGS, INC. (ASBP) scores 27/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-94.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-1,056.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ASPIRE BIOPHARMA HOLDINGS, INC. (ASBP) stock report — Zyberno Score 27/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:7.97
Market Cap:$8.27M

Valuation Multiples (3)

P/B Ratio:0.70x
P/S Ratio:1,333.74x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$3.54M
B. Profitability Assessment

Return Metrics (5)

ROA:-181.3%
Reinvestment Rate:-689.0%
Fundamental Growth Rate (g):7,281.2%

Margin Analysis (1)

Ebitda Margin:-312,016.9%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):100.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:7.99x
Quick Ratio:7.81x
Cash Ratio:7.22x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x
Debt-to-Equity Ratio:0.01x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-4.97x
Times Interest Earned:-4.97

Capital Structure (4)

Working Capital:11,779,348.00
Cash And Cash Equivalents:12,167,136.00
Long Term Debt:$0.00
Net Debt:-$11.81M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$6.20K
Cost Of Revenue Ttm:$6.32K

Profitability Breakdown (2)

-$116.00-$19.35M

Bottom Line Performance (3)

Net income TTM: -$11.05M
Linear Growth: 100.0%
📊 Click to view full ASBP Net Income analysis & methodology →
Income Before Tax:-$1.27M
Ebitda Ttm:-19,351,291.00

Operating Expenses (5)

Operating Expenses:7,294,860.00
R And D Expense:838,139.00
Sga Expense:4,158,860.00
Income Tax Expense:$1.01K
Interest Expense:3,893,197.00

Expense Ratios (3)

R And D To Revenue Percentage:1,328.2%
Sga To Revenue Percentage:6,590.5%
Ebitda Margin:-312,016.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$13.54M
Current Assets:$13.47M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:1,782,723.00
Current Liabilities:1,686,196.00
Long Term Debt:$0.00
Short Term Debt:$353.68K

Equity & Capital (3)

Equity:$11.76M
Retained Earnings:-$31.75M
Common Stock:490,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:288,450.00
Accounts Payable:972,108.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:157,500.00
C. Cash Flow Analysis

Operating Activities (2)

-$6.21M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$7.89M
Dividends Paid Ttm:0.00
Stock Repurchase:13,781,323.00

Capital Transactions (3)

Common Stock Issuance:8,951,119.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$10.65

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.01
Operating Cash Flow Per Share:-$4.74

Book Value & Capital (2)

Book Value Per Share:$11.33
Cash Per Share:11.72

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.00x
Working Capital Turnover Ttm:0.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:0.02x
Days Inventory Outstanding Ttm:16,664.17

Payables & Cash Cycle (2)

Days Payable Outstanding:56,160.09
Cash Conversion Cycle:-40,494.91
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-689.0%
Fundamental Growth Rate (g):7,281.2%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Net Income Growth Rate (Linear):100.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:ASBP
Company Name:ASPIRE BIOPHARMA HOLDINGS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:1.04M
Shares Outstanding Basic:1.04M
Shares Outstanding Diluted:1.04M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-23 04:18:44 UTC
Data Timestamp:2026-08-21T21:08:33.951432
Scroll to Top